Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...
1d
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results
Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including ...
In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Stocktwits on MSN
VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal?
Viridian Therapeutics Inc. (VRDN) shares tanked more than 41% in Monday’s pre-market trade after the company announced ...
A TYK2 inhibitor in development shows superior efficacy to placebo and apremilast for treating psoriasis, with no new safety ...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated ...
Mining Technology on MSN
Platina starts phase 3 aircore drilling at Mt McKenna in WA
The programme focuses on key areas of the project, particularly exploration Targets 2, 3, 4, and 5.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results